curiositas ad sanum Studien und Beratungs GmbH
- Address
- lock Available on a paid plan
curiositas ad sanum Studien und Beratungs GmbH
curiositas ad sanum Studien und Beratungs GmbH is a specialized clinical research center dedicated to advancing therapeutic solutions for neurological conditions. The center focuses on evaluating innovative treatments that significantly impact patients' quality of life, with particular emphasis on chronic pain and headache disorders.
- Chronic migraine prevention and management strategies
- Botulinum toxin therapy efficacy and safety assessment
- Neuropharmacological intervention trials
The research team conducts rigorous clinical trials to evaluate the effectiveness and safety profile of therapeutic interventions, including Dysport® (botulinum toxin type A) for the prevention of chronic migraine in adult populations. Their work centers on measuring clinically meaningful outcomes such as reduction in monthly migraine days, contributing valuable evidence to optimize treatment protocols for patients suffering from debilitating chronic headache conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Ipsen Innovation1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ipsen Innovation2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in curiositas ad sanum Studien und Beratungs GmbH
lock Showing 1 of 12 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease | Biohaven Therapeutics Ltd. | Phase IV | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Botulinum Toxin Type A - Haemagglutinin Complex | 1 | Unknown | 2024-03-18 | 2024-03-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.